Pharmafile Logo
Pharmafocus logo
Advanced Search

J&J

Showing 15 posts of 227 posts found.

J&J seek approval for first drug to treat high-risk smoldering myeloma

November 13, 2024
Research and Development FDA, J&J, Rare Diseases, bone marrow

Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and Drug Agency (FDA) and the …

News
lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

August 27, 2024
Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …

News

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

July 24, 2024
Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …

News

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

May 21, 2024
Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …

News

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024
Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …

News

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

News

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

March 11, 2024
Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …

News

J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment

February 12, 2024
Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …

News

J&J’s to submit surgical robot to FDA in 2024

November 8, 2023
Research and Development FDA, J&J, Johnson & Johnson MedTech, Pharmacy, surgical robot

Johnson & Johnson MedTech have announced plans to submit the Ottava robotic surgical system to the US Food and Drug …

News

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

News
pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

News

New warning added to J&J vaccine in US

July 13, 2021
Manufacturing and Production COVID-19, FDA, J&J, JJ, US, Vaccine

The FDA has made the decision to add a warning to the fact sheet for Johnson & Johnson’s COVID-19 vaccine, …

News

J&J’s Tremfya sees positive results for post-TNFi psoriatic arthritis

June 4, 2021
Medical Communications J&J, JJ

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …

News

J&J COVID-19 vaccine to resume Europe rollout

April 21, 2021
Research and Development COVID-19, COVID-19 vaccine, J&J, J&J vaccine, JJ, pharma, pharma news

The Johnson & Johnson COVID-19 vaccine will continue its rollout in Europe, following a review from the EMA.

News

EMA launch investigation into J&J’s COVID-19 vaccine amid US blood clot reports

April 12, 2021
Sales and Marketing COVID-19, EMA, J&J, JJ, Vaccine

The EMA is reviewing reports of rare blood clots in four people in the US who received Johnson & Johnson’s …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026